SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today ...

Jacobson and Gao recently published an excellent overview of adenosine receptors as therapeutic targets 1. In this commentary, we would like to identify some caveats in pre-clinical development of ...

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has led to the worst pandemic of the century. The high cumulative mortality of the coronavirus disease 2019 ...

The A2A adenosine receptor (A2AR) has been shown to be a critical and nonredundant negative regulator of immune cells in protecting normal tissues from inflammatory damage. We hypothesized that A2AR ...

In a case of biotech-on-biotech M&A action, Portage Biotech will acquire Tarus Therapeutics and its haul of adenosine receptor antagonists. Westport, Connecticut-based Portage will hand over 2.4 ...

Naturally rewarding stimuli (i.e. food, sex, etc) increase the activity of dopamine cells in the mesocorticolimbic dopamine system causing increased dopamine release in brain areas such as the nucleus ...

More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists in a standalone company helmed by a familiar leader. The offshoot, to be ...

Adenosine receptors may hasten inflammatory responses to tau pathology, according to a paper published this month in Brain. Researchers led by David Blum of the University of Lille, France, reported ...

Before researchers can develop targeted drugs, they need to know exactly how a disease works. Biochemist Bert Beerkens created molecules that allow them to find out. He used caffeine as the basis for ...

Adenosine is a vasoactive purine metabolite produced during breakdown of high-energy phosphates in hypoxia. Tissue levels of adenosine are 2–3 times higher in the fetus than the adult (1) and have ...